Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize or block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus (HPV) or from an immune system cell, said native E7 protein being locally immunosuppressive and/or angiogenic and said method comprising administering to a patient in need thereof, by the mucous membrane route, a vaccine pharmaceutical composition comprising:

• (i) an active compound selected from the group consisting of:
• said Immunosuppressive and/or angiogenic native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or also by adjuvant conditioning;
• an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein;
• a DNA molecule encoding said immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation;
• and
• a DNA molecule encoding an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein;
• and
• (ii) an adjuvant of mucosal immunity.